摘要
目的 对恶性骨肿瘤患者使用紫杉醇、唑来膦酸配合治疗的效果进行分析。方法 84例恶性骨肿瘤患者,采用随机抽样法分为常规组和研究组,每组42例。常规组采用紫杉醇进行治疗,研究组采用紫杉醇、唑来膦酸配合治疗。对比两组患者的疗效、不良反应发生情况、镇痛效果、疼痛程度、生活质量、血常规指标、血清癌胚抗原和血钙水平。结果 研究组总有效率95.24%高于常规组的78.57%(P<0.05)。研究组不良反应发生率4.76%低于常规组的23.81%(P<0.05)。研究组镇痛总有效率92.86%高于常规组的76.19%(P<0.05)。研究组治疗后3、6、12个月视觉模拟评分法(VAS)评分分别为(1.24±0.62)、(1.25±0.41)、(0.65±0.33)分,均低于常规组的(3.65±1.34)、(2.67±1.68)、(2.35±1.46)分(P<0.05)。治疗后,研究组社会功能、躯体功能、物质功能、心理功能评分分别为(79.81±7.26)、(87.69±7.45)、(85.41±6.28)、(85.37±7.69)分,均高于常规组的(70.21±6.24)、(75.31±6.58)、(74.24±6.85)、(77.15±7.08)分(P<0.05)。治疗后,研究组白细胞计数、血红蛋白、血小板计数分别为(7.20±1.21)×10^(9)/L、(126.78±12.26)g/L、(145.47±23.74)×10^(9)/L,均高于常规组的(5.39±2.29)×10^(9)/L、(100.25±13.17)g/L、(118.47±30.25)×10^(9)/L(P<0.05)。治疗后,研究组血清癌胚抗原、血钙水平分别为(35.54±11.60)ng/ml、(2.16±0.20)mmol/L,低于常规组的(44.42±11.65)ng/ml、(2.47±0.64)mmol/L(P<0.05)。结论 为恶性骨肿瘤患者使用紫杉醇、唑来膦酸配合治疗,可以减轻患者疼痛程度,镇痛效果良好,且可改善患者血常规指标及血清癌胚抗原、血钙水平,患者不良反应少,生活质量显著提高,疗效明显,可大力推广。
Objective To analyze the effect of paclitaxel and zoledronic acid in the treatment of malignant bone tumors.Methods 84 patients with malignant bone tumor were randomly divided into a conventional group and a study group,with 42 cases in each group.The conventional group was treated with paclitaxel,and the study group was treated with paclitaxel and zoledronic acid.The efficacy,adverse reactions,analgesic effect,pain intensity,quality of life,blood routine index,serum carcinoembryonic antigen and blood calcium levels were compared between the two groups.Results The total effective rate was 95.24%in the study group,which was higher than 78.57%in the conventional group(P<0.05).The incidence of adverse reactions was 4.76%in the study group,which was lower than 23.81%in the conventional group(P<0.05).The total effective rate of analgesia was 92.86%in the study group and 76.19%in the conventional group(P<0.05).The visual analogue scale(VAS)scores of the study group at 3,6 and 12 months after treatment were(1.24±0.62),(1.25±0.41)and(0.65±0.33)points,which were lower than(3.65±1.34),(2.67±1.68)and(2.35±1.46)points of the conventional group(P<0.05).After treatment,the scores of social function,physical function,material function and psychological function were(79.81±7.26),(87.69±7.45),(85.41±6.28)and(85.37±7.69)points in the study group,which were higher than(70.21±6.24),(75.31±6.58),(74.24±6.85)and(77.15±7.08)points in the conventional group(P<0.05).After treatment,the white blood cell count,hemoglobin count and platelet count of the study group were(7.20±1.21)×10^(9)/L,(126.78±12.26)g/L,and(145.47±23.74)×10^(9)/L,which were higher than(5.39±2.29)×10^(9)/L,(100.25±13.17)g/L and(118.47±30.25)×10^(9)/L of the conventional group(P<0.05).After treatment,the levels of serum carcinoembryonic antigen and blood calcium in the study group were(35.54±11.60)ng/ml and(2.16±0.20)mmol/L,which were lower than(44.42±11.65)ng/ml and(2.47±0.64)mmol/L in the conventional group(P<0.05).Conclusion The combined treatment of paclitaxel and zoledronic acid for patients with malignant bone tumors can reduce the pain of patients with good analgesic effect,and can improve the blood routine indicators,serum carcinoembryonic antigen and blood calcium levels of patients with fewer adverse reactions,significantly improve the quality of life of patients,and the efficacy is obvious,which can be vigorously promoted.
作者
丁妍妍
刘伟
DING Yan-yan;LIU Wei(Second Oncology Department,Tengzhou Central People's Hospital,Tengzhou 277599,China)
出处
《中国实用医药》
2024年第13期118-121,共4页
China Practical Medicine
关键词
紫杉醇
唑来膦酸
恶性骨肿瘤
疗效
Paclitaxel
Zoledronic acid
Malignant bone tumors
Curative effect
作者简介
通讯作者:刘伟。
